There are some questions about how effective Eli Lilly’s antibody neutralizing antibody bamlanivimab (LY-CoV555) will prove to be in the battle against Covid-19 due to labeling limitations.
A combination of Canadian drug developer Medicago’s experimental Covid-19 vaccine and a booster from Britain’s GlaxoSmithKline will enter a large study with more than 30,000 volunteers in 2020.
U.S. allows emergency use of first Covid-19 antibody drug
Adults 65 and Older, Business, Clinical Trials, COVID-19 antibody drugs, Dr. Anthony Fauci (Director), Emergency Use Authorization, FDA, Hospitalized COVID-19 Patients, Monoclonal Antibodies, R&D, Regeneron Pharmaceuticals, Shares, White HouseU.S. regulators authorized emergency use of the first experimental antibody drug for Covid-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
Common cold antibodies hold clues to Covid-19 behavior; lung scans speed Covid-19 diagnosis in stroke patients
Adults, Children, Common cold antibodies, Computed Tomography (CT) Scans, Coronavirus Disease 2019 (COVID-19), Covid-19 Pneumonia, Emergency Rooms, Hospitalized COVID-19 Patients, Infected Cells, Lung Imaging, Medical Journals, Novel Coronavirus, Science, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), StrokesIn a Reuters roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, common cold antibodies yield clues to Covid-19 behavior.
Johnson & Johnson plans to start testing the company’s experimental Covid-19 vaccine in youths aged 12 to 18 as soon as possible, a company executive said at a meeting held by the U.S. Centers for Disease Control and Prevention (CDC).
Covid-19 heart changes raise death risk; virus may be lead killer of young adults during surges
American College of Cardiology, Antibiotic overuse, Coronavirus, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Deaths, Data, Department of Health and Human Services (HHS), Doctors, Heart Injury, Hospitalized COVID-19 Patients, Outbreaks, R&D, U.S. Centers for Disease Control and Prevention, United States, Young AdultsIn a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, a new study may help identify which Covid-19 patients with signs of heart injury are at higher risk for death.
Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III Covid-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.
Alnylam Pharmaceuticals presented complete results from the company’s ILLUMINATE-B Phase III study in children under 6 years with primary hyperoxaluria type 1 (PH1), a rare disorder affecting the kidneys.
Roche’s Venclexta Granted Full Approval Under Project Orbis and Real-Time Review
Accelerated Approval, Acute Myeloid Leukemia (AML), Adults 75 or older, Approvals, B-cell lymphoma-2 (BCL-2) protein, Chemotherapy, Clinical Trials, FDA/Regulatory, Full Approval, Project Orbis, R&D, Real-Time Oncology Review (RTOR) PilotThe U.S. Food and Drug Administration granted Roche’s Venclexta (venetoclax) full approval in combination with azacytidine, or decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia in adults 75 years or older.
Pfizer and Opko Health reported their Phase III clinical trial of somatrogan met the primary endpoint compared to Genotropin (somatropin) for treating children 3 to 18 years of age with growth hormone deficiency (GHD).